-
Posted by
Two Blokes Jun 10 -
Filed in
Stock
-
1 view
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy company listed in London, has reported that its Parsortix system has been central to three new pieces of research exploring how cancer spreads and how new treatments could target that process. The Parsortix device is used to capture and analyse circulating tumour cells (CTCs), which are cancer cells that break away from tumours and enter the bloodstream.
